Home » Stocks » MOR

MorphoSys AG (MOR)

Stock Price: $30.66 USD 0.87 (2.92%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $29.97 -0.69 (-2.25%) Jan 27, 7:05 AM
Market Cap 4.03B
Revenue (ttm) 302.73M
Net Income (ttm) 26.75M
Shares Out 32.72M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE 322.58
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $30.66
Previous Close $29.79
Change ($) 0.87
Change (%) 2.92%
Day's Open 30.51
Day's Range 30.39 - 30.77
Day's Volume 21,933
52-Week Range 18.86 - 35.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 2 weeks ago

PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced th...

Other stocks mentioned: INCY
Accesswire - 2 weeks ago

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a lead...

Accesswire - 2 weeks ago

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in...

Seeking Alpha - 1 month ago

High-Yield equity REITs have regularly underperformed. We expect that trend to continue over the next decadeREITs with high yields, low FFO multiples, and weak balance sheets have regularly un...

Other stocks mentioned: KBWY, PFF, VNQ
Accesswire - 1 month ago

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / December 17, 2020 / MorphoSys AG: Corporate Calendar 2021 Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2021 as follows:   Public...

Seeking Alpha - 2 months ago

MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.

Other stocks mentioned: INCY
Business Wire - 2 months ago

MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (N...

Other stocks mentioned: INCY, XNCR
Business Wire - 4 months ago

Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST

Other stocks mentioned: INCY
Seeking Alpha - 5 months ago

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

Zacks Investment Research - 6 months ago

Profitability analysis is considered one of the best possible ways to assess the prospects of a company.

Other stocks mentioned: HELE, PFSI, TPL
Zacks Investment Research - 8 months ago

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

Other stocks mentioned: INCY
Seeking Alpha - 8 months ago

MorphoSys AG (MPSYF) CEO Jean Kress on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 8 months ago

The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.

Other stocks mentioned: INCY
Seeking Alpha - 10 months ago

MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.

Seeking Alpha - 1 year ago

MorphoSys AG's (MOR) CEO Simon Moroney on Q4 2018 Results - Earnings Call Transcript

About MOR

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatme... [Read more...]

Industry
Biotechnology
IPO Date
Mar 9, 1999
CEO
Simon Moroney
Employees
640
Stock Exchange
NASDAQ
Ticker Symbol
MOR
Full Company Profile

Financial Performance

In 2019, MorphoSys's revenue was $71.76 million, a decrease of -6.13% compared to the previous year's $76.44 million. Losses were -$103.01 million, 83.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MorphoSys stock is "Buy." The 12-month stock price forecast is 36.70, which is an increase of 19.70% from the latest price.

Price Target
$36.70
(19.70% upside)
Analyst Consensus: Buy